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ABSTRACT
To evaluate the potential of allogeneic hematopoietic cell transplantation (HCT) with a reduced-intensity
conditioning regimen (RIST) for the treatment of patients with hematologic malignancies not in remission, we
retrospectively reviewed the medical records of 132 patients (89 leukemia or myelodysplastic syndrome, 40
malignant lymphoma, and 3 others) who received conventional myeloablative HCT (CST, n  52) or RIST
(n  80). The median age of the RIST group was significantly higher than that of the CST group (53 years
versus 40 years, P < .01). The RIST group also included a higher proportion of patients with an HCT-specific
comorbidity index (HCT-CI) of 1 or more than the CST group (65% versus 37%, P  .03). The probabilities
of achieving complete remission and the incidences of grades II-IV and III-IV acute graft-versus-host disease
(aGVHD) in the CST and RIST groups were, respectively, 77% and 64%, 50% and 50%, and 23% and 28%,
with no significant differences. Similarly, there was no difference in the 2-year probabilities of nonrelapse
mortality (NRM, 36% and 38%), progressive disease or relapse (PD 51% and 49%), overall survival (OS, 31%
and 38%), and progression-free survival (PFS, 28% and 29%). Multivariate analyses revealed that a higher
HCT-CI score and transplant from donors other than HLA-matched relatives were associated with increased
risks of NRM and poor OS, and patients who received chemotherapy within 2 months before HCT were
associated with increased risks of PD, poor OS, and PFS after transplantation. After adjusting for these
variables, the risks of NRM, PD, OS, and PFS in the RIST group were not significantly different from those
in the CST group. In conclusion, these results suggest that the antileukemia/lymphoma effect associated with
RIST is comparable to that associated with CST. RIST appears to be feasible for the treatment of hematologic
malignancies not in remission.
© 2007 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) has the potential to achieve long-term cure of
ematologic malignancies by pretransplant condition-
ng and a graft-versus-leukemia/lymphoma (GVL) ef-
ect. It has been well established that the disease status p
32t the time of transplantation is the most important
rognostic factor, and the rates of relapse and nonre-
apse mortality (NRM) signiﬁcantly increase in pa-
ients with hematologic malignancies who were not in
emission. Therefore, conventional stem cell trans-
lantation (CST) using a myeloablative conditioning
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CST versus RIST for non-CR Hematologic Malignancies 933egimen has been universally used in the hope of
aximally reducing the tumor burden before HCT in
atients not in remission. However, CST may not be
n option for many patients because of their older age
r associated comorbidities. Alternatively, over the
ast few years, nonmyeloablative and reduced-inten-
ity conditioning stem cell transplantation (RIST)
ave been offered to these patients undergoing HCT,
n the assumption that RIST would be better toler-
ted [1-4].
There have been several reports that the outcome
f older patients who underwent RIST while in re-
ission was comparable to that of patients who re-
eived CST [5-9], which suggests that the GVL effect
ssociated with RIST might be adequate for control-
ing chemosensitive or slowly progressing disease. On
he other hand, it still remains controversial whether
IST is feasible for patients not in remission, al-
hough small pilot studies have shown that RIST was
nsuccessful for advanced hematologic malignancies
3,10-14]. To address this issue, we retrospectively
nalyzed 132 patients who were not in remission at the
ime of CST or RIST.
ATIENTS AND METHODS
tudy Patients
We retrospectively reviewed the medical records
f 132 patients with various hematologic malignancies
ho underwent allogeneic HCT (CST, n 52; RIST,
 80) while not in remission at our institution from
anuary 2000 to December 2004. Patients with
hronic myelogenous leukemia (CML) in the chronic
hase, myelodysplastic syndrome (MDS)-refractory
nemia, and those with lymphoma in partial remission
PR) were not included because the response to treat-
ent and the outcome of these patients is generally
onsidered to be similar to those in patients who are in
omplete remission (CR). Bone marrow or granulo-
yte colony-stimulating factor (G-CSF)-mobilized pe-
ipheral blood stem cells (PBSC) were harvested from
onors according to protocols approved by the guide-
ines of the Japan Marrow Donor Program, the Japa-
ese Society for Hematopoietic Cell Transplantation,
nd the Japanese Society of Blood Transfusion. In-
ormed consent was obtained according to the Decla-
ation of Helsinki.
ransplantation Procedures
The conditioning regimens used in CST included
he combination of cyclophosphamide (CY; 60 mg/kg
.v. daily for 2 days) and fractionated total body irra-
iation (TBI; 12 Gy in 6 fractions over 3 days) in 34
atients, CY and oral busulfan (BU; 16 mg/kg divided
ver 4 days) in 13 patients, and other combinations in
patients (Table 1). Targeted dose adjustment of BU [as not performed. Patients who underwent RIST
ere older than 50 years of age or those who had
omorbidities or prior transplantation. The condi-
ioning regimens for RIST consisted of ﬂudarabine
30 mg/m2 i.v. daily for 6 days) or cladribine (0.11
g/kg i.v. daily for 6 days) plus 8 mg/kg of oral BU
15] with (n  27) or without (n  53) 4 Gy TBI. In
apan, only bone marrow is permitted as a stem cell
ource in transplantation from an unrelated healthy
olunteer donor. In the setting of nonmyeloablative
tem cell transplantation from an unrelated donor,
he sustained engraftment rate has been reported to
e lower for recipients of bone marrow than for those
iven PBSC [13]. Therefore, low-dose TBI was also
dded to the conditioning regimen for RIST from an
nrelated donor to facilitate engraftment.
Day 0 was deﬁned as the day of stem cell infusion.
-CSF was administered after transplantation in all
atients until neutrophil engraftment. Most patients
ho underwent CST were given cyclosporine (CSP)
ith methotrexate (MTX) [16], and all patients who
nderwent RIST were given CSP with or without
TX for graft-versus-host disease (GVHD) prophyl-
xis (Table 1). GVHD was treated with 1 to 2 mg/kg/
ay prednisolone equivalents, resumption of full-dose
SP administration if applicable, or both. Initial doses
f corticosteroids and tapering schedules of immuno-
uppressive medications were modiﬁed at the discre-
ion of the attending physicians according to the pres-
nce or absence of malignant cells and the severity of
VHD. Treatment for relapse after transplantation
as left to the discretion of the attending physicians.
All patients received ciproﬂoxacin (200 mg orally 3
imes daily) for bacterial prophylaxis until neutrophil
ngraftment. Fluconazole (100 mg once daily) was ad-
inistered for fungal prophylaxis. Patients who had pos-
tive serologic test results for herpes simplex virus or
aricella zoster virus received prophylactic low-dose acy-
lovir until the cessation of immunosuppressive agents
17]. Prophylaxis against Pneumocystis jiroveci infection
as provided with trimethoprim-sulfamethoxazole from
he ﬁrst day of conditioning to day 3 of transplanta-
ion, and from day 28 until day 180 or the cessation of
mmunosuppressive agents. Patients were monitored
ith weekly cytomegalovirus (CMV) pp65 antigenemia
esting, and positive antigenemia was treated with gan-
iclovir as described previously [18,19].
efinitions
Chemotherapy within 2 months before HCT was
eﬁned as chemotherapy to control the disease except
or rituximab alone for lymphoma and imatinib me-
ylate alone for CML. Pretransplantation comorbidi-
ies were determined by the HCT-speciﬁc comorbid-
ty index (HCT-CI) [20] with a minor modiﬁcation
21]. Neutrophil engraftment was deﬁned as the ﬁrst
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D. Maruyama et al.934able 1. Patient Characteristics
CST RIST P-Value
o. of patients 52 80
ex, male/female 25/27 50/30
edian age, years (range) 40 (3-55) 53 (20-68) <.01
isease status at conditioning, N (%)
AML 20 (38) 15 (19)
Relapse 1 12 6
Relapse >2 5 5
Primary refractory 3 4
MDS (including overt AML) 15 (29) 24 (30)
Relapse 1 1 2
Untreated 6 11
Primary refractory 8 11
ALL 5 (10) 2 (3)
Relapse 1 4 1
Relapse 2 1 1
CML 5 (10) 3 (4)
Accelerated phase 3 0
Blastic crisis 2 3
NHL 7 (13) 33 (40)
Relapse 1 2 6
Relapse >2 2 16
Primary refractory 3 11
Others* 0 3 (4)
hemotherapy within 2 months before HCT, N (%) 33 (63) 52 (65)
Leukemia/MDS 30 23
Lymphoma 3 26
Others* 0 3
CT-CI score, N (%) .03
0 33 (63) 28 (35)
1-2 11 (21) 31 (39)
>3 8 (16) 21 (26)
onditioning regimen, N (%)
TBI/CY 34 (65) 0
BU/CY 13 (25) 0
Fludarabine-based ( TBI)† 0 68 (85)
Cladribine-based (TBI)‡ 0 12 (15)
Others 5 (10) 0
onor type, N (%) .1
HLA-matched related donor 17 (33) 41 (51)
HLA-mismatched related donor 5 (9) 7 (9)
Unrelated donor 30 (58) 32 (40)
tem cell source, N (%) <.01
G-CSF mobilized PBSC 21 (40) 49 (61)
BM 27 (52) 20 (25)
CB 4 (8) 11 (14)
VHD prophylaxis, N (%) <.01
Cyclosporine§ 1 (2) 52 (65)
Cyclosporine/MTX¶ 49 (94) 28 (35)
Tacrolimus 1 (2) 0
Tacrolimus/MTX 1 (2) 0
rior HCT, N (%) 4 (8) 8 (10) .65
ST indicates conventional stem cell transplantation; RIST, reduced-intensity stem cell transplantation; AML, acute myelogenous leukemia;
MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin’s
lymphoma; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplantation-speciﬁc comorbidity index; TBI,
total-body irradiation; CY, cyclophosphamide; BU, busulfan; HLA, human leukocyte antigen; G-CSF, granulocyte colony-stimulating
factor; PBSC, peripheral blood stem cell; BM, bone marrow; CB, cord blood; GVHD, graft-versus-host disease; MTX, methoterexate.
Others included 1 chronic lymphocytic leukemia and 2 multiple myeloma patients.
Twenty-three patients received 4 Gy TBI.
Four patients received 4 Gy TBI.
Including 7 with antithymocyte globulin.
Including 10 with antithymocyte globulin.
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CST versus RIST for non-CR Hematologic Malignancies 935f 3 consecutive days after transplantation that the
bsolute neutrophil count exceeded 0.5  109/L of
eripheral blood. The diagnosis and clinical grading
f acute and chronic GVHD (aGVHD, cGVHD)
ere performed according to established criteria [22-
4]. CR was deﬁned as lower than 5% blasts in the
one marrow, with a neutrophil count 1.5  109/L
nd a platelet count 100  109/L in leukemia/MDS
atients, and according to the International Work-
hop Criteria [25] in lymphoma patients.
tatistical Analysis
The endpoints of the study were progressive dis-
ase/relapse (PD), NRM, overall survival (OS), and
rogression-free survival (PFS). OS, NRM, and PD
ere deﬁned as the time between stem cell infusion to
he event. PFS was deﬁned as the time between stem
ell infusion to PD or death from any cause, which-
ver occurred earlier. OS and PFS were estimated by
he Kaplan-Meier method [26]. NRM and PD were
stimated by the cumulative incidence. The chi-
quare test or Fisher’s exact test was used to evaluate
he differences in the clinical characteristics of the
ST and RIST groups. The log-rank test and the gen-
ralized Wilcoxon test were used to compare the
robabilities of survival, NRM, and PD after HCT
ver time across patient subgroups.
Multiple Cox regression models were used for
ultivariate risk factor analysis for PD, NRM, OS,
nd PFS after HCT. Clinical factors evaluated in the
D, NRM, OS, and PFS analyses were patient age at
he time of HCT (continuous), HCT-CI (0, 1-2, 3 or
ore), conditioning (CST, RIST), donor (HLA-
atched related, HLA-mismatched related or unre-
ated), disease type (leukemia/MDS, lymphoma), and
hemotherapy within 2 months before HCT (yes, no).
ogistic regression analysis was performed to identify
rognostic factors that were associated with the
chievement of CR. In addition to the variables exam-
ned in the Cox analysis, blast percentage (20%,
20%) in the bone marrow or peripheral blood and
he serum lactate dehydrogenase (LDH) level (nor-
al, elevation) before HCT were included for the
nalysis of CR in patients with leukemia/MDS and
hose with lymphoma, respectively. We considered
-sided P-values of .05 to be statistically signiﬁcant.
tatistical analyses were performed with the SAS ver-
ion 8.2 (SAS Inc, Cary, NC).
ESULTS
atient Characteristics
The characteristics of all patients who underwent
ST (n  52) or RIST (n  80) are summarized in
able 1. The median age of the RIST group wasigniﬁcantly higher than that of the CST group (53 [ears versus 40 years, P  .01). A large number of
atients in both groups had acute myeloid leukemia
AML) or MDS (CST 67%, RIST 49%), and the
IST group included a higher population of patients
ith malignant lymphoma (CST 13%, RIST 40%).
ll malignant lymphomas (n  40) were non-
odgkin’s lymphoma, including aggressive (n  16),
ighly aggressive (n  15), and indolent (n  9)
ymphomas. The distribution of lymphoma subtypes
as similar between the 2 groups. Disease status at
ransplantation included primary refractory (n  42),
efractory relapse (n  65), blastic crisis, or acceler-
ted phase of CML (n  8) and untreated disease
n  17). The distribution of disease status and the
roportion of patients who received chemotherapy
ithin 2 months before HCT were similar between
he 2 groups. The RIST group contained higher pro-
ortions of patients with an HCT-CI score of 1 or
ore (CST 37%, RIST 65%) and those who received
-CSF-mobilized PBSC (CST 40%, RIST 61%)
han the CST group.
In the leukemia/MDS patients (n  89), the me-
ian percentage of blasts (82 patients in bone marrow
nd 7 patients in peripheral blood) in both groups
ere similar (CST 29%, RIST 30%). In patients with
alignant lymphoma, serum LDH was elevated above
he upper normal limit in 3 of 7 (43%) in the CST
roup compared to 23 of 33 (70%) in the RIST group.
ngraftment and GVHD
The clinical course and response are detailed in
able 2. The median duration of follow-up in surviv-
ng patients is 1123 days (range: 367-2044 days) in the
ST group and 899 days (range: 334-1961 days) in
he RIST group. Neutrophil engraftment was ob-
erved in 48 patients (92%) and 75 patients (94%), at
median of 17 days and 12 days, respectively. En-
raftment was not conﬁrmed in the remaining 9 pa-
ients because of death or PD within 28 days after
CT. The incidences of grade II-IV and grade III-IV
GVHD were similar in the CST and RIST groups
50% versus 50% and 23% versus 28%, respectively).
he incidences of cGVHD and chronic extensive
VHD were also similar (46% versus 49% and 34%
ersus 38%, respectively).
isease Response
The probabilities of achieving CR as the best re-
ponse were similar after CST and RIST (77% and
4%, respectively) (Table 2). To examine the possible
isk factors for achieving CR, we separately analyzed
atients with leukemia/MDS and those with lym-
homa using a logistic regression analysis (Table 3).
onditioning regimen (RIST) did not inﬂuence the
R rate in patients with leukemia/MDS (odds ratioOR] 1.11, 95% conﬁdence interval [CI] 0.40-3.07,
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D. Maruyama et al.936 .84) or in those with lymphoma (OR 0.29, 95%
I 0.05-1.75, P  .18). In the leukemia/MDS pa-
ients, those who received chemotherapy within 2
onths before HCT (OR 0.32, 95% CI 0.09-1.05,
 .06) and transplant from donors other than an
LA-matched relative (OR 0.28, 95% CI 0.08-1.06,
 .06) tended to have a lower CR rate, whereas the
able 2. Clinical Course and Response
CST (N  52) RIST (N  80)
edian follow-up of
surviving
patients, days 1123 (367–2044) 899 (334–1961)
ngraftment of
neutrophils,
N (%) 48 (92) 75 (94)
Median day (range) 17 (10–35) 12 (5–43)
cute GVHD, N (%)
Grade II–IV 26 (50) 40 (50)
Grade III–IV 12 (23) 22 (28)
R*, N (%) 40 (77) 51 (64)
Leukemia/MDS (n 
89), CR/total 35/45 35/44
Lymphoma (n  40),
CR/total 5/7 14/33
auses of NRM, N (%) 15 (29) 26 (33)
GVHD 6 11
Infection
fungus 0 4
CMV 0 1
bacterial 4 7
Interstitial
pneumonitis 2 1
Others† 3 2
ST indicates conventional stem cell transplantation; RIST, re-
duced-intensity stem cell transplantation; GVHD, graft-versus-
host disease; MDS, myelodysplastic syndrome; CR, complete
remission; NRM, nonrelapse mortality; CMV, cytomegalovirus.
CR as the best response after transplantation.
Others included acute myocardial infarction, subarachnoid hem-
orrhage, and pulmonary alveolar haemorrhage in the CST
group, and cerebral hemorrhage and unknown in the RIST
group.
able 3. Logistic Analysis of CR Rate in Leukemia/MDS and Lympho
Leu
Odds R
CT-CI 0
1–2 1.44 (
3 or more 0.96 (
ge 1.00 (
onditioning RIST 1.11 (
onor Alternative* 0.28 (
hemotherapy within 2
months before HCT Yes 0.32 (
lasts† >20% 0.62 (
erum LDH level Elevation
DS indicates myelodysplastic syndrome; HCT-CI, hematopoietic
stem cell transplantation; LDH, lactate dehydrogenase; CI, con
Non-HLA-matched related donor.
Blast counts in bone marrow (N  82) or peripheral blood (N  7).last percentage (20%) of bone marrow or periph-
ral blood was not associated with the CR rate. In
ymphoma patients, chemotherapy within 2 months
efore HCT was the only factor that was signiﬁcantly
ssociated with a low CR rate (OR 0.04, 95% CI
.005-0.40, P  .01), whereas serum LDH elevation
id not inﬂuence the CR rate.
As shown in Figure 1, the cumulative incidence of
D was not signiﬁcantly different between the CST
nd RIST groups. The 2-year probabilities of PD
ere 51% in the CST group and 49% in the RIST
roup, which were not signiﬁcantly different
P  .76). Cox regression analysis was performed to
dentify factors that were associated with PD. Multi-
ariate analyses in all patients showed that those who
eceived chemotherapy within 2 months before HCT
ere associated with an increased risk of PD (hazard
atio [HR] 3.93, 95% CI 1.97-7.83, P  .01) (Table
). After adjusting for these variables, the intensity of
onditioning (CST or RIST) did not inﬂuence the
ate of PD in any of the patients. To further evaluate
he association between risk factors and outcome, we
erformed a subset analysis in patients who underwent
ST or RIST. As a result, chemotherapy within 2
ents
/MDS (N  89) Lymphoma (N  40)
% CI) P Odds Ratio (95% CI) P
1.00
.87) .56 3.33 (0.66–16.7) .14
.35) .95 2.22 (0.40–12.3) .36
.04) .70 1.02 (0.97–1.07) .49
.07) .84 0.29 (0.05–1.75) .18
.06) .06 0.95 (0.26–3.42) .93
.05) .06 0.04 (0.005–0.40) <.01
.80) .38
0.35 (0.09–1.34) .12
ansplantation-speciﬁc comorbidity index; RIST, reduced-intensity
interval.
igure 1. Cumulative incidence of PD. The 2-year probabilities of
D in the CST (51%) and RIST (49%) groups were not signiﬁ-
antly different (P  .76).ma Pati
kemia
atio (95
1.00
0.43–4
0.28–3
0.97–1
0.40–3
0.08–1
0.09–1
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CST versus RIST for non-CR Hematologic Malignancies 937onths before HCT was associated with an increased
isk of PD only in the RIST group, and not in the
ST group (Table 5).
RM
Major causes of NRM for patients in both groups
ere GVHD and infection (Table 2). More patients
ied of fungal infection in the RIST group compared
o the CST group, but the 2-year probabilities of
RM were not signiﬁcantly different (36% and 38%,
 .50, Figure 2 ). A Cox regression analysis was
erformed to identify factors associated with NRM.
ultivariate analyses in all patients showed that a
igher HCT-CI score (1 or more) and transplant from
n HLA-mismatched related or unrelated donor (al-
able 4. Multivariate Analysis of PD, NRM, OS, and PFS in All Pat
Covariates* N
PD
HR (95% CI) P HR
onditioning
CST 52 1.00
RIST 80 0.91 (0.53-1.55) .72 0.99 (
CT-CI score
0 65
1-2 38 3.25 (
3 or more 29 6.61 (
onor
MRD 58
Alternative† 74 2.77 (
hemotherapy within
2 months before
HCT
No 47 1.00
Yes 85 3.93 (1.97-7.83) <.01
D indicates progressive disease or relapse; NRM, nonrelapse morta
CST, conventional stem cell transplantation; RIST, reduced-in
tation-speciﬁc comorbidity index; MRD, HLA-matched related
Factors analyzed included age at the time of HCT (continuous),
Alternative), disease type (leukemia/MDS, lymphoma) and chem
Non-HLA-matched related donor.
able 5. Multivariate Analysis of Outcomes after HCT in the CST an
Covariates
D Chemotherapy within 2 months before HCT
RM HCT-CI (1–2)
HCT-CI (3 or more)
Alternative donor*
S HCT-CI (1–2)
HCT-CI (3 or more)
Alternative donor*
FS HCT-CI (3 or more)
Chemotherapy within 2 months before HCT
Alternative donor*
D, indicates progressive disease or relapse; NRM, nonrelapse mort
CST, conventional stem cell transplantation; RIST, reduced-int
HCT-CI, hematopoietic cell transplantation-speciﬁc comorbidiNon-HLA-matched related donor.ernative donor) were associated with an increased risk
f NRM (Table 4). After adjusting for these variables,
he intensity of conditioning (CST or RIST) did not
nﬂuence the rate of NRM in any of the patients. A
ubset analysis revealed that a higher HCT-CI score
1 or more) was associated with increased NRM in the
ST group, but not in the RIST group (Table 5). In
ontrast, transplant from an alternative donor was
ssociated with increased NRM in the RIST group,
ut not in the CST group.
urvival
The 2-year probabilities of OS and PFS were not
igniﬁcantly different between the CST and RIST
roups (31% and 38%, P  .98, for OS; 28% and
OS PFS
I) P HR (95% CI) P HR (95% CI) P
1.00 1.00
96) .99 0.95 (0.60-1.51) .83 0.95 (0.63-1.43) .79
1.00 1.00
40) <.01 1.76 (1.08-2.89) .02
.2) <.01 2.62 (1.51-4.56) <.01 1.63 (1.02-2.62) .04
1.00
54) <.01 1.80 (1.15-2.82) .01
1.00 1.00
1.73 (1.10-2.72) .02 2.23 (1.44-3.45) <.01
S, overall survival; PFS, progression-free survival; HR, hazard ratio;
stem cell transplantation; HCT-CI, hematopoietic cell transplan-
; HCT, hematopoietic cell transplantation.
I (0, 1–2, 3, or more), conditioning (CST, RIST), donor (MRD,
py within 2 months before HCT (yes, no).
Groups
CST (N  52) RIST (N  80)
(95% CI) P HR (95% CI) P
NS 6.16 (2.15–17.7) <.01
(1.26–16.0) .02 NS
(2.91–35.7) <.01 2.41 (1.14–5.10) .02
NS 4.63 (1.96–10.9) <.01
(1.23–5.90) .01 NS
(1.97–11.9) <.01 NS
NS 3.04 (1.73–5.35) <.01
(1.01–5.04) .04 NS
(1.05–4.19) .03 2.10 (1.19–3.70) .01
NS 1.79 (1.06–3.00) .03
S, overall survival; PFS, progression-free survival; HR, hazard ratio;
tem cell transplantation; HCT, hematopoietic cell transplantation;
x; NS; not signiﬁcant.ients
NRM
(95% C
1.00
0.51-1.
1.00
1.43-7.
2.88-15
1.00
1.39-5.
lity; O
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D. Maruyama et al.9389%, P  .89, for PFS), as shown in Figure 3 and
igure 4. The 2-year probabilities of PD, OS, and
FS were not signiﬁcantly different between patients
ho developed grade III-IV aGVHD and those who
id not (37% and 44%, P  .39, for PD; 33% and
0%, P  .07, for OS; 27% and 41%, P  .24, for
FS). On the other hand, the 2-year probability of
RM in patients who developed grade III-IV
GVHD was signiﬁcantly higher than that in those
ho did not (56% and 21%, P  .004). We also
valuated outcomes in patients who had AML or
DS (CST, n  35; RIST, n  39). There was no
igniﬁcant difference in the 2-year probabilities of PD
50% and 51%), OS (37% and 33%), and PFS (34%
nd 22%) between the CST and RIST groups. On the
ther hand, the 2-year probability of NRM in the
IST group was signiﬁcantly higher than that in the
ST group (52% and 23%, P  .03).
Multivariate analyses in all patients showed that a
igher HCT-CI score (1 or more) and transplant from
n alternative donor were associated with poor OS,
nd patients who received chemotherapy within 2
onths before HCT were associated with poor OS
nd PFS (Table 4). After adjusting for these variables,
he risks of OS and PFS were not signiﬁcantly differ-
nt between the CST and RIST groups. Disease type
leukemia/MDS or lymphoma) was not a signiﬁcant
igure 2. Cumulative incidence of NRM. The 2-year probabilities
f NRM in the CST (36%) and RIST (38%) groups were not
igniﬁcantly different (P  .50).
igure 3. Estimated OS according to the conditioning regimen.
he 2-year probabilities of OS in the CST (31%) and RIST (38%)groups were not signiﬁcantly different (P  .98).actor for OS or PFS. Furthermore, subset analyses
evealed that a higher HCT-CI score (1 or more) was
ssociated with poor OS and PFS in the CST group,
ut not in the RIST group (Table 5). In contrast,
ransplant from an alternative donor was associated
ith increased NRM in the RIST group, but not in
he CST group. Patients who received chemotherapy
ithin 2 months before HCT had a poor PFS in both
roups.
ISCUSSION
Our results suggest that the antileukemia/lym-
homa effect of RIST might be comparable to that of
ST for hematologic malignancies that are not in
emission. We found that a higher HCT-CI score and
ransplant from an alternative donor were associated
ith increased risks of NRM and poor OS, and pa-
ients who received chemotherapy within 2 months
efore HCT because of the acceleration of disease
rogression were associated with increased risks of
D, poor OS, and PFS. The estimated rates of NRM,
D, OS, and PFS in the RIST group were not signif-
cantly different from those in the CST group even
hough the patients who received RIST were signiﬁ-
antly older and had signiﬁcantly higher HCT-CI
cores than those who received CST. Several reports
ave described a similar OS rate in older patients who
nderwent RIST and CST because the lower NRM
ate was offset by a higher PD [5,27,28]. In contrast,
cott et al. [7] found no signiﬁcant differences in OS,
FS, PD, or NRM between CST and RIST in pa-
ients with MDS/AML.
In this study, disease response to the transplanta-
ion procedure was similar between the CST and
IST groups when the CR rate is considered the best
esponse, as were the rate and timing of PD. Whereas
ome reports have shown that PD after HCT was
ncreased in patients who underwent RIST compared
o CST [3,5,11], others have found no signiﬁcant
ifference [6-8,29]. This discrepancy might result
rom the differences in disease status at the time of
igure 4. Estimated PFS according to the conditioning regimen.
he 2-year probabilities of PFS in the CST (28%) and RIST (29%)
roups were not signiﬁcantly different (P  .89).
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CST versus RIST for non-CR Hematologic Malignancies 939ransplantation and the intensity of the conditioning
egimens. In our study, the median percentage of
lasts in leukemia/MDS patients and the distribution
f serum LDH levels in lymphoma patients were com-
arable between the CST and RIST groups. The
roportion of patients who required chemotherapy
ithin 2 months before HCT was similar in the 2
roups. Overall, the risk of disease progression was
omparable. The lack of a signiﬁcant difference in PD
etween the CST and RIST groups in our study may
e because the reduced-intensity regimens used in our
tudy were more intense than those in previous re-
orts. Nevertheless, our results suggest that RIST has
comparable antileukemia/lymphoma activity through a
VL effect compared to CST.
Our study found that chemotherapy within 2
onths before HCT was the only factor that signiﬁ-
antly predicted a lower CR rate in lymphoma pa-
ients and tended to be associated with a lower CR
ate in leukemia/MDS patients. Furthermore, chemo-
herapy within 2 months before HCT was also asso-
iated with a worse prognosis not only with regard to
D but also for OS and PFS. A subset analysis showed
hat this negative impact of recent chemotherapy was
nly seen in RIST patients, and not in CST patients,
hich suggests that the tempo of the progression of
he disease before HCT is especially important in
IST patients. Wong et al. [30] reported that high
eripheral blast counts (30%) in patients with AML/
DS were associated with poor event-free survival
nd OS after HCT regardless of the conditioning
egimen. In our study, however,20% of blasts in the
one marrow or peripheral blood and serum LDH
evel elevation did not have a signiﬁcant impact on the
R rate in leukemia/MDS and lymphoma patients,
espectively.
In our study, there was no signiﬁcant difference in
RM between the CST and RIST groups, which was
n contrast to previous reports showing that reduced-
ntensity regimens were associated with less organ
amage, and thus contributed to less NRM
1,4,5,9,27,31-34]. There are several possible explana-
ions for this discrepancy. First, the patients who re-
eived RIST were older and had a higher HCT-CI
core than those in the CST group. Second, the re-
uced-intensity conditioning (RIC) we used was more
oxic than “truly nonmyeloablative” conditioning. Fi-
ally, we tapered immunosuppressive medications
apidly, especially in the RIST group, in an attempt to
nduce a more potent GVL effect, which resulted in
ore severe GVHD and subsequent infectious com-
lications. However, our data showed that grade III-IV
GVHD did not contribute to a reduction in the rate of
D or to an overall improvement in survival, which was
onsistent with a previous report [14], although a high
ate of NRM in patients with severe aGVHD may have
asked its competing event (ie, PD). eWe conﬁrmed that HCT-CI was a signiﬁcant risk
actor for NRM and OS in patients not in remission.
CT-CI has recently been introduced to evaluate
retransplant comorbidities in HCT recipients, which
redict well NRM and OS after allogeneic HCT [20].
n this study, the proportion of patients who were not
n remission and were associated with comorbidities
as 53%, which was higher than the value (42%) in
ur previous report [21], probably because these pa-
ients tended to be heavily pretreated and were forced
o pursue HCT in the hope of a rare cure. Interest-
ngly, this negative impact of HCT-CI was only seen
n patients who underwent CST, and not in those who
nderwent RIST. Our data imply that RIC may be
referable in patients with hematologic malignancies
ot in remission and with a high HCT-CI score by
educing early NRM after transplantation.
Transplant from an alternative donor was another
rognostic factor for NRM and OS in this study,
hich is consistent with previous reports [12,35-38].
urthermore, an increased risk of NRM and OS as-
ociated with alternative donors was observed only in
atients who underwent RIST. There are several pos-
ible explanations. First, the Japan Marrow Donor
rogram allows the donation of bone marrow, but not
BSC, from volunteer donors, which has been re-
orted to be associated with poor engraftment and
orse outcomes after nonmyeloablative stem cell
ransplantation [13]. Second, our conditioning regi-
en including low-dose TBI for RIST from an alter-
ative donor was more toxic than that for RIST from
n HLA-matched related donor. Further studies are
equired to establish optimized conditioning regimens
nd GVHD prophylaxis for RIST in unrelated pair
ettings.
In 27 patients who had all of these risk factors (ie,
hemotherapy within 2 months beore HCT, HCT-CI
core of 1 or more, and transplant from an alternative
onor), the 2-year probabilities of NRM, PD, and OS
ere 56%, 44%, and 21%, respectively, with no sig-
iﬁcant differences between the CST and RIST
roups (data not shown). Therefore, the indications
or transplantation in patients with multiple risk fac-
ors should be carefully determined.
This study has several inherent limitations. First,
he eligibility requirements for CST and RIST were
ifferent. Most patients who received RIST were con-
idered ineligible for CST because of age or comorbid
onditions. Second, factors other than the condition-
ng regimen were not entirely comparable between
he 2 groups, that is, patient age, underlying diagnosis
leukemia/MDS and lymphoma), donor selection,
tem cell source, and GVHD prophylaxis. Third,
ome of the conventional cytoreductive conditioning
egimens we used (ie, use of oral BU and lack of its
harmacologic monitoring) may no longer be consid-
red optimal. Fourth, because the reduced-intensity
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D. Maruyama et al.940egimens used in our study were more intense than
hose in previous reports, our data may not be gener-
lized to the concept of “reduced-intensity regimen”
nd there may be circumstances where PD would be
ore marked. Finally, the follow-up of patients in this
tudy was too short to draw any deﬁnite conclusions.
evertheless, the observed data may still be useful in
valuating the impact of RIST on disease control in
atients suffering from a higher risk of disease pro-
ression after transplantation.
In conclusion, our results suggest that the antileu-
emia/lymphoma effect associated with RIST might
e comparable to that of CST for hematologic malig-
ancies not in remission, particularly when patients do
ot require chemotherapy within 2 months before
CT or they had a higher HCT-CI score. To deter-
ine the ultimate utility of speciﬁc conditioning reg-
mens, controlled prospective trials are needed, with
nrolled patients being stratiﬁed according to disease
ctivity, hematopoietic stem cell source, and associ-
ted comorbidities.
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